Business Context and Reporting Period
Company: Galmed Pharmaceuticals Ltd.
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Three and nine months ended September 30, 2024
Business Overview: Galmed is a biopharmaceutical company focused on developing Aramchol for liver diseases (specifically Primary Sclerosing Cholangitis) and exploring oncological and cardiac fibrosis indications. The company also collaborates on Amilo-5MER. It has no approved products and has not generated product sales revenue.
Key Financial Metrics
| Metric (USD in thousands) | 9 Months Ended Sept 30, 2024 | 9 Months Ended Sept 30, 2023 | 3 Months Ended Sept 30, 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(4,308) | $(4,896) | $(1,914) |
| Operating Expenses | $(4,634) | $(5,341) | $(2,011) |
| Research & Development | $(1,907) | $(2,448) | $(738) |
| General & Administrative | $(2,727) | $(2,893) | $(1,273) |
| Financial Income (Net) | $326 | $445 | $97 |
| Cash & Equivalents (Sept 30, 2024) | $9,724 | - | - |
| Total Current Assets (Sept 30, 2024) | $17,685 | - | - |
| Accumulated Deficit (Sept 30, 2024) | $(197,260) | - | - |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately 12% ($0.6 million) for the nine months ended September 30, 2024, compared to the same period in 2023.
- Expense Management: Total operating expenses decreased by 13% ($0.7 million) year-over-year for the nine-month period. R&D expenses dropped 21% primarily due to reduced clinical trial costs following the discontinuation of the Open Label Part of the ARMOR Study.
- Liquidity Improvement: Cash and cash equivalents increased significantly from $2.9 million at December 31, 2023, to $9.7 million at September 30, 2024. Total current assets rose from $13.2 million to $17.7 million.
- Capital Structure: The company executed a 1-for-12 reverse stock split in August 2024. Share count increased from 573,745 to 1,506,992 shares (retroactively adjusted) due to the exercise of warrants and issuance of shares under a Standby Equity Purchase Agreement (SEPA).
Guidance, Outlook, and Risks
- Strategic Pivot: Following Phase 3 ARMOR Study results, the company plans to broaden development activities into two new programs: Aramchol-based combinations for colorectal/hepatic cancers and cardiac fibrosis. Data from these programs is expected in Q4 2024.
- Liquidity Outlook: Management estimates current cash resources will support operations for more than 12 months from the filing date. However, substantial additional capital is required for future trials and commercialization.
- Financing Activities: The company entered a SEPA with YA II PN, LTD. in August 2024, initially for $10 million, amended in October 2024 to $20 million. As of November 14, 2024, approximately $4.5 million in gross proceeds had been raised under this agreement.
- Risks: Key risks include the uncertainty of clinical trial outcomes, regulatory approval delays, the need for future financing, and geopolitical instability in the Middle East affecting operations.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $17.2 million in liquid assets against the projected costs of the new oncology and cardiac fibrosis programs.
- SEPA Utilization: Monitor the pace of share issuances under the amended $20 million SEPA and potential dilution impact.
- Strategic Execution: Confirm the release of new data from the in-vitro and ex-vivo studies for the new indications in Q4 2024.
- OnKai Investment: Review the status of the $1.5 million investment in OnKai and the subsequent $250,000 bridge loan entered into in October 2024.
- Regulatory Status: Track any updates regarding the re-initiation or modification of the ARMOR Study for PSC.